Notably, in bladder cancer, the discovery of new targets paved the way to various clinical trials that explored the use of ADCs directed against Nectin-4, Trop-2, or HER-2 with significant clinical benefits in terms of overall response and survival [72,73]. This evidence concerns the gene TACSTD2 and urinary bladder carcinoma.